References
- Package leaflet: information for the patient; Humira 40 mg solution for injection in pre-filled pen; Adalimumab [Internet]. [cited 2021 Apr 22]. Available from 2021 Apr 22: https://www.medicines.org.uk/emc/files/pil.272.pdf
- Package leaflet: information for the user enbrel 25 mg solution for injection in pre-filled syringe Enbrel 50 mg solution for injection in pre-filled syringe; etanercept [Internet]. [[cited 2021 Apr 22]. Available from: https://www.medicines.org.uk/emc/files/pil.272.pdf
- Kirkham B, Furst DE, Romain PLR. Tumor necrosis factor-alpha inhibitors: an overview of adverse effects [Internet]. UpToDate. 2020 [cited 2021 Apr 22]. Available from: https://www-uptodate-com.proxy.library.uu.nl/contents/tumor-necrosis-factor-alpha-inhibitors-an-overview-of-adverse-effects
- Kosse LJ, Weits G, Vonkeman HE, et al. Immune-mediated inflammatory disease patients’ preferences in adverse drug reaction information regarding biologics. Expert Opin Drug Saf [Internet]. 2020 [cited 2021 Apr 22];19(8):1–5. Available from: https://pubmed.ncbi.nlm.nih.gov/32524887/
- Carmona L, Descalzo MA, Ruiz-Montesinos D, et al. Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0. Rheumatology [Internet]. 2011 [cited 2021 May 6];50(1):85–92. Available from: https://pubmed.ncbi.nlm.nih.gov/20601654/
- García-Doval I, Hernández MV, Vanaclocha F, et al. Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts. Br J Dermatol [Internet]. 2017 [cited 2021 Apr 22];176(3):643–649. Available from: https://pubmed.ncbi.nlm.nih.gov/27258623/
- Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis [Internet]. 2013 [cited 2021 May 6];72(4):517–524. Available from: https://pubmed.ncbi.nlm.nih.gov/22562972/
- Baeten D, Van Hagen PM. Use of TNF blockers and other targeted therapies in rare refractory immune-mediated inflammatory diseases: evidence-based or rational? [Internet]. Ann. Rheum. Dis. Ann Rheum Dis; 2010 [cited 2021 May 6]. p. 2067–2073. Available from: https://pubmed.ncbi.nlm.nih.gov/20705637/
- Kosse LJ, Jessurun NT, Vonkeman HE, et al. Stakeholders’ perspectives on a patient-reported outcome measure-based drug safety monitoring system for immune-mediated inflammatory diseases. Expert Opin Drug Saf [Internet]. 2020 [cited 2021 Apr 22];19(11):1521–1528. Available from: https://pubmed.ncbi.nlm.nih.gov/32730115/
- Kosse LJ, Jessurun NT, Hebing RCF, et al. Patients with inflammatory rheumatic diseases: quality of self-reported medical information in a prospective cohort event monitoring system. Rheumatol (United Kingdom) [Internet]. 2020 [cited 2021 Apr 22];59:1253–1261. Available from: https://pubmed.ncbi.nlm.nih.gov/31566226/
- Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Int J Surg [Internet]. 2014 [cited 2021 Jun 9];12(12):1500–1524. Available from: https://pubmed.ncbi.nlm.nih.gov/25046751/
- van Lint JA, Jessurun NT, Hebing RCF, et al. Patient-reported burden of adverse drug reactions attributed to biologics used for immune-mediated inflammatory diseases. Drug Saf [Internet]. 2020 [cited 2021 May 17];43(9):917–925. Available from: https://doi.org/10.1007/s40264-020-00946-z
- van Lint JA, Jessurun NT, Tas SW, et al. Gastrointestinal adverse drug reaction profile of etanercept: real world data from patients and healthcare professionals. J Rheumatol [Internet]. 2021 [cited 2021 Jun 20];201373. Available from: https://www.jrheum.org/content/early/2021/05/11/jrheum.201373
- Brown EG, Wood L, Wood S. The Medical Dictionary for Regulatory Activities (MEDDRA) [Internet]. Drug Saf. Drug Saf; 1999 [cited 2021 May 19]. p. 109–117. Available from: https://pubmed.ncbi.nlm.nih.gov/10082069/
- Fisher R. Tests of significance in harmonic analysis. 1929 [cited 2021 May 19]; Available from: https://hekyll.services.adelaide.edu.au/dspace/bitstream/2440/15201/1/75.pdf
- Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B [Internet]. 1995 [cited 2021 May 19];57:289–300. Available from: https://rss.onlinelibrary.wiley.com/doi/full/10.1111/j.2517-6161.1995.tb02031.x
- Jafari M, Ansari-Pour N. Why, when and how to adjust your P values? Cell J [Internet]. 2019 [cited 2021 May 19];20:604–607. Available from: https://pmc/articles/PMC6099145/
- Roest L, Kosse L, Van Lint J, et al. Disease-specific adverse drug reaction profiles of adalimumab and etanercept as reported by immune-mediated inflammatory disease patients. Ann Rheum Dis [Internet]. 2021 [cited 2021 Jun 21];80:548–549. Available from: http://ard.bmj.com/
- Patanè M, Ciriaco M, Chimirri S, et al. Interactions among low dose of methotrexate and drugs used in the treatment of rheumatoid arthritis. Adv Pharmacol Sci. 2013;2013. DOI:10.1155/2013/313858.
- Gibofsky A. Combination therapy for rheumatoid arthritis in the era of biologicals. HSS J [Internet]. 2006 [cited 2021 Jun 21];2(1):30–41. Available from: https://pmc/articles/PMC2504107/
- Wolfe F, Michaud K. Corticosteroids increase the risk of diabetes mellitus in RA and contribute to the risk of myocardial infarction and heart failure. Ann Rheum Dis - BMJ Publ Gr [Internet]. 2004 [cited 2021 Jun 21];63:495. Available from: https://www.researchgate.net/publication/216742242_Corticosteroids_increase_the_risk_of_diabetes_mellitus_in_RA_and_contribute_to_the_risk_of_myocardial_infarction_and_heart_failure
- Radovits BJ, Kievit W, Fransen J, et al. Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis [Internet]. 2009 [cited 2021 May 19];68(9):1470–1473. Available from: https://pubmed.ncbi.nlm.nih.gov/19015210/
- Akhondi H, Varacallo M. Rheumatoid arthritis and ankylosing spondylitis [Internet]. StatPearls. StatPearls Publishing; 2018 [cited 2021 Jul 5]. Available from 2021 Jul 5: http://www.ncbi.nlm.nih.gov/pubmed/30335321
- Inman RD, El-Gabalawy HS. The immunology of ankylosing spondylitis and rheumatoid arthritis: a tale of similarities and dissimilarities. Clin Exp Rheumatol [Internet]. 2009 [cited 2021 Jul 5];27. Available from: https://pubmed.ncbi.nlm.nih.gov/19822042/
- Gäwert L, Hierse F, Zink A, et al. How well do patient reports reflect adverse drug reactions reported by rheumatologists? Agreement of physician- and patient-reported adverse events in patients with rheumatoid arthritis observed in the German biologics register. Rheumatology (Oxford) [Internet]. 2011 [cited 2021 Sep 12];50(1):152–160. Available from: https://pubmed.ncbi.nlm.nih.gov/20871128/
- Thomas PWA, Römkens TEH, West RL, et al. Discrepancy between patient- and healthcare provider-reported adverse drug reactions in inflammatory bowel disease patients on biological therapy. Uni Euro Gastro J [Internet]. 2021 [cited 2022 Jan 4];9(8):919–928. Available from: https://onlinelibrary-wiley-com.proxy.library.uu.nl/doi/full/10.1002/ueg2.12107
- Dejcman D, Skowasch D, Pizarro C, et al. Pulmonary manifestations of rheumatoid arthritis, psoriatic arthritis and peripheral spondyloarthritis: prevalence, diagnostic approach and treatment options. Curr Rheumatol Rev [Internet]. 2021 [cited 2021 Jul 16];17(1):17–28. Available from: https://pubmed.ncbi.nlm.nih.gov/32888273/
- Bluett J, Jani M, Symmons DPM. Practical management of respiratory comorbidities in patients with rheumatoid arthritis. Rheumatol Ther [Internet]. 2017 [cited 2021 Jul 16];4(2):309. Available from: https://pmc/articles/PMC5696283/
- Jani M, Hirani N, Matteson EL, et al. The safety of biologic therapies in RA-associated interstitial lung disease. Nat Rev Rheumatol [Internet]. 2013. [cited 2021 Jul 16];10(5):284–294. Available from: https://www-nature-com.proxy.library.uu.nl/articles/nrrheum.2013.197
- Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety trial of adalimumab in rheumatoid arthritis). J Rheumatol. 2003;30(12):2563–2571.
- Mease PJ, Gladman DD, Collier DH, et al. Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial. Arthritis Rheumatol [Internet]. 2019 [cited 2021 Jul 18];71(7):1112–1124. Available from: https://onlinelibrary-wiley-com.proxy.library.uu.nl/doi/full/10.1002/art.40851
- Klareskog L, van der Heijde D, de Jager J, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet [Internet]. 2004 [cited 2021 Jul 18];363(9410):675–681. Available from: https://pubmed.ncbi.nlm.nih.gov/15001324/
- Parakkal D, Stobaugh DJ, Ehrenpreis ED. Infectious complications of TNF-α inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the food and drug administration adverse event reporting system. J Gastrointestin Liver Dis [Internet]. 2013 [cited 2021 Jul 18];22:269–276. Available from: https://www.jgld.ro/jgld/index.php/jgld/article/view/2013.3.8/619
- Gerriets V, Bansal P, Goyal A, et al. Tumor Necrosis Factor Inhibitors. StatPearls [Internet]. 2021 [cited 2021 Jul 18]; Available from: https://www.ncbi.nlm.nih.gov/books/NBK482425/.
- Li P, Zheng Y, Chen X. Drugs for autoimmune inflammatory diseases: from small molecule compounds to anti-TNF biologics. Front Pharmacol. 2017:460.
- Ethgen O, de L EF, Bruyere O, et al. What do we know about the safety of corticosteroids in rheumatoid arthritis? Curr Med Res Opin. 2013 Jul 18;29:1147–1160.
- Vela P, Sanchez-Piedra C, Perez-Garcia C, et al. Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: data from the BIOBADASER III register. Arthritis Res Ther [Internet]. 2020 [cited 2021 Jul 18];22(1):1–9. Available from: https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-020-02231-x
- Cho S-K, Sung Y-K, Kim D, et al. Drug retention and safety of TNF inhibitors in elderly patients with rheumatoid arthritis. BMC Musculoskelet Disord [Internet]. 2016 [cited 2021 Jul 18];17(1):1–8. Available from: https://pmc/articles/PMC4977640/
- Methotrexate 2.5 mg tablets - summary of product characteristics (smpc) - (emc) [internet]. Electron. Med. Compend. 2020 [cited 2022 May 26]. Available from 2022 May 26: https://www.medicines.org.uk/emc/product/511/smpc
- de CMC, Barros BCA, Fulone I, et al. Adverse events in patients with rheumatoid arthritis and psoriatic arthritis receiving long-term biological agents in a real-life setting. Front Pharmacol [Internet]. 2019 [cited 2021 Jul 19];10:965. Available from: https://pmc/articles/PMC6749844/
- van de PLBA, Atkins C, Malaise M, et al. Efficacy and safety of Adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis [Internet]. 2004 [cited 2021 Jul 19];63(5):508–516. Available from: https://ard.bmj.com/content/63/5/508
- Thalayasingam N, Isaacs JD. Anti-TNF therapy. Best Pract Res Clin Rheumatol [Internet]. 2011 [cited 2022 Jun 1];25:(4):549–567. Available from: https://pubmed.ncbi.nlm.nih.gov/22137924/
- Johnson KJ, Sanchez HN, Schoenbrunner N. Defining response to TNF-inhibitors in rheumatoid arthritis: the negative impact of anti-TNF cycling and the need for a personalized medicine approach to identify primary non-responders [Internet]. Clin Rheumatol Springer London. 2019 [cited 2021 Jun 30]. 2967–2976. Available from: https://pubmed.ncbi.nlm.nih.gov/31520227/
- Rubbert-Roth A, Atzeni F, Masala IF, et al. TNF inhibitors in rheumatoid arthritis and spondyloarthritis: are they the same? Autoimmun Rev. 2018;17(1):24–28.
- Atzeni F, Benucci M, Sallì S, et al. Different effects of biological drugs in rheumatoid arthritis. Autoimmun Rev [Internet]. 2013 [cited 2021 Jul 17];12:(5):575–579.